Virtu Financial BD LLC recently announced the acquisition of new stake in Statera Biopharma Inc. (NASDAQ:STAB). This fresh investment now brings its stake to 0.19% valued currently at $14334.0. In addition, Two Sigma Securities LLC raised its holdings by 87150.0 to 98638.0 shares. And UBS Securities LLC has lifted its position by 1,044.62% or 89346.0 shares – to 97899.0 shares.
With over 9.81 million Statera Biopharma Inc. (STAB) shares trading Tuesday and a closing price of $0.14 on the day, the dollar volume was approximately $1.37 million. The shares have shown a negative half year performance of -38.86% and its price on 11/29/22 gained nearly 20.82%. Currently, there are 50.23M common shares owned by the public and among those 45.96M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for STAB have a consensus price objective of $40.00. The analysts have set the share’s price value over the next 12 months at a high of $40.00 and a low of $40.00. But an upside of 99.65% will see the stock hit the forecast high price target while median target price for the stock is $40.00.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Statera Biopharma Inc. are Vanguard Extended Market Index Fu, iShares Core S&P Total US Stock M, and SunAmerica Series Trust – SA T Ro. Vanguard Extended Market Index Fu owns 0.38 million shares of the company’s stock, all valued at over $53015.0. SunAmerica Series Trust – SA T Ro bought 49500.0 shares to bring its total holdings to over 61200.0 shares at a value of $8568.0. SunAmerica Series Trust – SA T Ro now owns shares totaling to 0.12% of the shares outstanding.
However, the script later moved the day high at 0.1470, up 20.82%. The company’s stock has a 5-day price change of 43.03% and -25.47% over the past three months. STAB shares are trading -93.84% year to date (YTD), with the 12-month market performance down to -95.52% lower. It has a 12-month low price of $0.09 and touched a high of $3.47 over the same period. STAB has an average intraday trading volume of 3.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.73%, 1.84%, and -50.01% respectively.
Institutional ownership of Statera Biopharma Inc. (NASDAQ: STAB) shares accounts for 5.40% of the company’s 50.23M shares outstanding. Mutual fund holders own 1.30%, while other institutional holders and individual stakeholders account for 4.25% and 0.11% respectively.
It has a market capitalization of $7.22M and a beta (3y monthly) value of 0.96. The earnings-per-share (ttm) stands at -$1.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.31% over the week and 15.65% over the month.
The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.
Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
